AKT1 and cancer: Inhibition of PI3K/Akt/mTOR signaling is a current therapeutic focus, particularly in hormone-driven cancers such as breast and prostate cancer, where targeting this pathway can enhance the efficacy of existing chemotherapies and immunotherapies[15].